Creator: Help Dementia Editorial Team
Published: 2026-04-06T01:42:00

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

Pet therapy sits at the center of this dementia and brain health question.

The claim that pet therapy dogs reduce agitation better than most medications is appealing, but the research tells a more nuanced story. While some studies do show benefits for dementia-related agitation, recent meta-analyses and systematic reviews do not support the idea that pet therapy dogs consistently outperform medications. The evidence is mixed—benefits are real and measurable in some domains like depression and overall behavioral symptoms, but when it comes specifically to agitation, the data doesn’t yet support superiority over pharmaceutical interventions. For a family watching their loved one struggle with behavioral disturbances, the honest answer matters more than the hopeful one. Consider the case of Margaret, a 78-year-old with moderate Alzheimer’s disease who became increasingly aggressive and restless in the afternoons. Her family brought in a therapy dog twice weekly.

In her case, the dog provided clear benefit—Margaret’s restlessness decreased, and she engaged more with staff and visitors. But Margaret’s experience, while real and valuable, is not the same as proof that dogs work better than her existing medication. Some residents show dramatic improvement; others show modest changes or none at all. This variability is what the research actually documents. The problem with oversimplifying the evidence is that it can lead families to abandon effective medications in favor of therapy dogs, or to delay implementing both interventions together. Understanding what therapy dogs actually do—and what they don’t—helps caregivers make better decisions for the individuals in their care.

What Does the Research Actually Say About Pet Therapy Dogs and Dementia-Related Agitation?
Why Some Studies Show Benefits While Meta-Analyses Raise Caution
Who Responds Best to Pet Therapy Dogs, and Who Might Not Benefit
How Pet Therapy Dogs Complement Medication Rather Than Replace It
Important Limitations and Risks of Pet Therapy That Deserve Discussion
What Happens When Therapy Dog Programs Stop? Sustainability Questions
Where the Evidence Is Heading and What This Means for Dementia Care
Conclusion

What Does the Research Actually Say About Pet Therapy Dogs and Dementia-Related Agitation?

Multiple studies have examined pet therapy interventions for dementia, and the results vary significantly depending on study design and measurement methods. A 26-patient study found statistically significant reduction in agitation when a therapy dog was present (p = 0.006), suggesting the intervention does have measurable effects for some individuals. A smaller 15-resident pilot study documented statistically significant decreases in agitated behaviors and increased social interaction after three weeks of daily animal-assisted therapy. These findings seem promising on the surface. However, a larger 2022 meta-analysis that pooled data from 11 randomized controlled trials and 825 participants found significant reductions in depression and behavioral symptoms overall, but notably found no significant improvement in agitation specifically.

This is the critical distinction: the meta-analysis confirmed that therapy animals help with mood and general behavioral issues, but the data did not show they outperform medications for agitation in particular. A 2024 evidence mapping review that comprehensively searched the literature through December 2024 concluded there is “insufficient evidence regarding efficacy and safety”—a more cautious assessment than many popular accounts suggest. The intervention reversal studies provide some of the clearest data. When animal-assisted therapy was withdrawn from some residents, agitation increased by a relative 11.9%. When the therapy was reintroduced, agitation decreased by a relative 29.9%. This pattern—showing measurable change related to the intervention’s presence or absence—is meaningful but does not establish that therapy dogs outperform medication alternatives.

What Does the Research Actually Say About Pet Therapy Dogs and Dementia-Related Agitation?

Why Some Studies Show Benefits While Meta-Analyses Raise Caution

The difference between individual studies and meta-analyses reflects a crucial limitation of dementia research. Individual studies of therapy animals often involve small participant groups, short durations, and inconsistent measurement methods. A 15-person study can show dramatic benefits that don’t replicate when the same protocol is tested with 200 people. Additionally, many early animal-assisted therapy studies lacked rigorous controls, making it difficult to distinguish effects of the dog from effects of increased attention and structured activity time. This is where the limitation becomes important: when you pool many studies together to see the overall pattern, the strong findings often shrink.

Benefits that seemed robust in a 26-person study become marginal in analysis of thousands of participants. A 2025 systematic review did find that animal-assisted therapy provides significant improvements in psychological and behavioral symptoms in Alzheimer’s patients, suggesting the intervention does work—but improvement in “behavioral symptoms” is broader than the specific question of agitation control versus medications. The research community has also documented that robotic animal therapy can decrease psychoactive and pain medication use in dementia patients, which is valuable. But decreased use is not the same as superior effectiveness. If a therapy dog allows some reduction in medication, that’s a clinical win worth noting. But the evidence doesn’t show that a therapy dog alone replaces medication entirely, or that it controls agitation better than medication alone.

Who Responds Best to Pet Therapy Dogs, and Who Might Not Benefit

Not all dementia patients respond to therapy dogs equally. Some individuals—like Margaret in our earlier example—show genuine calming effects, increased engagement, and reduced agitation. Others remain unresponsive or indifferent. Still others may have allergies, phobias, or prior negative experiences with dogs that make the intervention inappropriate or even harmful. Residents with less advanced dementia and those with some retained ability to recognize and bond with animals tend to show the strongest response. Patients in very advanced stages, where responsive engagement has diminished across all domains, may not benefit from animal-assisted therapy in measurable ways.

Prior to implementing a therapy dog program, careful assessment of individual preferences, medical contraindications, and cognitive capacity is essential. A resident afraid of dogs will not be calmed by being near one, regardless of the handler’s training. Additionally, the quality of the human handler matters significantly. A trained, calm, knowledgeable handler creates a very different experience than an untrained volunteer with a behavioral problem dog. The therapeutic value comes not solely from the dog’s presence but from the structured, calm interaction the trained team facilitates. This human element is often underemphasized in popular discussions of “pet therapy” but is essential to actual outcomes.

Who Responds Best to Pet Therapy Dogs, and Who Might Not Benefit

How Pet Therapy Dogs Complement Medication Rather Than Replace It

For most dementia care settings, the appropriate question is not whether to choose between a therapy dog or medication, but how to use both strategically. A 2023 meta-analysis looking at robotic animal therapy noted medication reduction as a benefit, not replacement. This suggests the realistic role: therapy dogs may allow a reduction in medication dose or frequency, potentially decreasing side effects while maintaining behavioral control through a combination of pharmaceutical and non-pharmaceutical approaches. Some facilities report that residents requiring high doses of antipsychotic medications show modest improvement in agitation when a therapy dog program is added, sometimes allowing a slight reduction in medication.

This is clinically valuable because antipsychotics carry known risks—increased stroke risk, metabolic effects, and cognitive dulling. If a therapy dog can help achieve behavioral control with a lower medication dose, that’s a genuine benefit. But the comparison should be “therapy dog plus medication versus medication alone,” not “therapy dog versus medication.” The practical tradeoff is this: therapy dog programs require trained staff or volunteers, consistent scheduling, space for the dog, liability management, and ongoing care and training for the animal. Medication requires a prescription, but once prescribed, delivers consistent dosing without requiring human scheduling or specialized training. For many underfunded care facilities, the infrastructure and cost of a therapy dog program may be more challenging to sustain than medication management, even if the outcomes were equal.

Important Limitations and Risks of Pet Therapy That Deserve Discussion

One significant limitation is infection risk. Dementia residents often have compromised immune systems, poor hygiene practices, or increased vulnerability to infections. Therapy dogs can carry pathogens and create infection exposure that medication does not. Facilities implementing animal therapy programs must manage rigorous cleaning protocols and veterinary health standards for the animals. For frail, elderly residents, this risk is non-trivial. Another limitation often overlooked: some residents become distressed or anxious around animals.

A dog that barks unexpectedly or jumps can trigger fear, agitation, or aggression in residents with underlying anxiety or trauma histories. The same intervention that calms one person can escalate another. This is why the blanket claim that therapy dogs reduce agitation “better than medications” is problematic—medications (when chosen well) can be titrated for individual response; therapy dogs are a one-size-fits-most intervention that doesn’t work for everyone. Additionally, the research on training standards for “dementia-specific” therapy dogs remains sparse. Unlike service dogs for people with mobility disabilities, which have formalized training standards and certification, therapy dogs often have variable training levels. A dog trained to remain calm around elderly people is not necessarily trained to respond to the specific behavioral patterns of someone with advanced dementia. This gap between marketing claims about “specially trained” dogs and the actual evidence about what training produces optimal dementia outcomes is a real concern.

Important Limitations and Risks of Pet Therapy That Deserve Discussion

What Happens When Therapy Dog Programs Stop? Sustainability Questions

The intervention reversal studies mentioned earlier offer a practical warning. When therapy dog programs were discontinued, agitation increased again—not permanently, but demonstrably. This suggests that therapy dogs manage agitation temporarily through their presence but do not create lasting behavioral change once withdrawn. Medication, by contrast, continues to work as long as it’s taken. This isn’t a criticism of therapy dogs but a realistic assessment: they require ongoing implementation to maintain benefit.

For care facilities considering therapy dog programs, sustainability is critical. A volunteer-dependent program that loses its key handler or dog is vulnerable to collapse. A family planning to bring a therapy dog to a loved one needs realistic expectations about the time, commitment, and cost involved over months and years. Some facilities and families have successfully maintained these programs as part of permanent care plans; others have launched them with initial enthusiasm only to discontinue them when volunteer availability or funding declined. The research benefits documented in the literature often come from controlled research settings where consistency and staff support were maximized—not from typical care facility conditions.

Where the Evidence Is Heading and What This Means for Dementia Care

Recent research is becoming more rigorous and skeptical of simplistic claims about animal-assisted therapy. The 2024 evidence mapping study, which comprehensively reviewed the field through late 2024, concluded with measured language about “insufficient evidence”—a shift from earlier reviews that sometimes overstated the benefits. This pattern reflects how scientific understanding evolves: initial studies generate enthusiasm, but larger and better-controlled trials often show more modest effects.

The future of animal-assisted therapy in dementia likely involves better identification of which individuals and which behavioral patterns respond best, clearer protocols around handler training standards, and honest integration with medication management rather than positioning as an alternative. Research into robotic animals is expanding partly because robots avoid infection risks and require no ongoing care, offering some of the documented benefits of animal presence without certain practical barriers. None of this diminishes the real comfort and connection that therapy dogs provide to many dementia residents—but it frames that benefit honestly, without exaggerated claims.

Conclusion

Pet therapy dogs provide real and measurable benefits for many dementia residents, particularly in reducing depression, increasing social engagement, and improving overall behavioral function. However, the research does not support the claim that therapy dogs reduce agitation better than medications. Individual studies show promise, but meta-analyses and systematic reviews indicate that benefits for agitation specifically are not consistently superior to pharmaceutical interventions. For dementia care to be optimal, the question should not be dogs or medication, but rather how to combine both approaches strategically to maximize quality of life while managing medication risks.

If you are considering therapy dog programs for a care facility or for a loved one, the evidence supports their use as a complement to medication, not as a replacement. Assess individual response carefully, ensure proper handler training and consistency, and set realistic expectations. The most effective dementia care integrates multiple approaches—skilled medication management, structured activities, meaningful relationships, environmental design, and yes, when appropriate and feasible, trained therapy animals. The evidence supports this comprehensive approach far more robustly than it supports any single intervention alone.